Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Wet Age-related Macular Degeneration: later-stage trial registry
2 of 9 indexed Wet Age-related Macular Degeneration trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Wet Age-related Macular Degeneration: 9 US clinical trials tracked, 2 recruiting.
Wet Age-related Macular Degeneration is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Kodiak Sciences, running 2 of these trials.
Enrollment posture brief
Registry condition wet-age-related-macular-degeneration
OPEN 2 | RECR 22% | LATE 5 | EARLY 3 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acne (22% recruiting · 27 trials)
Wet Age-related Macular Degeneration lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Wet Age-related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Wet Age-related Macular Degeneration is recruiting below its size-band peers.
2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Wet Age-related Macular Degeneration research.
Kodiak Sciences accounts for 2 of 9 trials (22.2%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Wet Age-related Macular Degeneration enrolment sits around 400 participants.
Median target enrolment is 400 among the 9 trials that report a genuine target (sentinel values excluded). 3 of those (33.3%) plan for fewer than 100 participants.
-
Wet Age-related Macular Degeneration research is mostly interventional.
8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
AbbVie
NCT05407636
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
AbbVie
NCT04704921
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Kodiak Sciences
NCT06556368
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
EyePoint Pharmaceuticals
NCT06668064
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
EyePoint Pharmaceuticals
NCT06683742
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
NexThera Co.
NCT06704009
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Adverum Biotechnologies
NCT04645212
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Kodiak Sciences
NCT04964089
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
NeoVista
NCT00679445
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Wet Age-related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Wet Age-related Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Wet Age-related Macular Degeneration page
9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Wet Age-related Macular Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kodiak Sciences sponsors the most Wet Age-related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See Kodiak Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Wet Age-related Macular Degeneration condition card totals 9 registered trials; most-linked intervention Aflibercept (2.0 mg); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.